Betatrophin对非酒精性脂肪性肝病的预测价值

张利利; 高福来

doi:10.3969/j.issn.1001-5256.2018.12.024

Betatrophin对非酒精性脂肪性肝病的预测价值

DOI: 10.3969/j.issn.1001-5256.2018.12.024

秦皇岛市第一医院消化内科

基金项目:

秦皇岛市科技项目(201602A144)；

详细信息

中图分类号: R575
计量
- 文章访问数: 1461
- HTML全文浏览量: 2
- PDF下载量: 300
- 被引次数: 0
出版历程
- 出版日期: 2018-12-20

Value of betatrophin in predicting nonalcoholic fatty liver disease

Research funding:

摘要

摘要:
目的探讨Betatrophin预测非酒精性脂肪性肝病（NAFLD）的价值。方法选取2017年1月-2018年1月在本院诊治的NAFLD患者160例作为研究对象,分为低脂肪含量组（LFC,n=65）和高脂肪含量组（HFC,n=95）,另选取健康人群72例作为对照组。检测空腹血糖（FPG）、糖化血红蛋白（HbA1c）、TC、TG、HDL-C、LDL-C、ALT、AST、肌酐（Cr）、尿素氮（BUN）、尿酸（UA）和Betatrophin水平。计量资料多组间比较采用单因素方差分析,两两比较采用LSD-t检验,计数资料多组间比较采用χ2检验。血清Betatrophin与其他生化指标的相关性检验采用Pearson分析,采用多元线性逐步回归分析法分析影响脂肪含量的独立危险因素。结果LFC组和HFC组血清Betatrophin水平分别为（269. 3±15. 4） pg/ml、（290. 2±30. 5） pg/ml,明显高于对照组[（250. 2±20. 1）pg/ml,F=16. 134,P <0. 001],且HFC组高于LFC组（P <0. 05）。血清Betatrophin水平...
- 脂肪肝 /
- Betatrophin /
- 相关性分析
Abstract:
Objective To investigate the value of betatrophin in predicting nonalcoholic fatty liver disease (NAFLD) . Methods A total of160 patients with NAFLD who were diagnosed and treated in our hospital from January 2017 to January 2018 were enrolled in this study and were divided into low fat content (LFC) group with 65 patients and high fat content (HFC) group with 95 patients. A total of 72 healthy individuals were enrolled as control group. Related indices were measured, including fasting plasma glucose (FPG) , HbA1 c, total cholesterol (TC) , triglyceride (TG) , high-density lipoprotein cholesterol (HDL-C) , low-density lipoprotein cholesterol (LDL-C) , alanine aminotransferase (ALT) , aspartate aminotransferase (AST) , creatinine (Cr) , blood urea nitrogen (BUN) , uric acid (UA) , and betatrophin.Comparison between multiple groups was made by one-way analysis of variance, and comparison between any two groups was made using the LSD-t test, comparison of categorical data between multiple groups was made by chi-square test. Pearson analysis was performed to investigate the correlation of serum betatrophin with other biochemical parameters, and multivariate linear stepwise regression analysis was used to analyze the independent risk factors for fat content. Results The LFC group and the HFC group had a significantly higher serum level of betatrophin than the control group (269. 3 ± 15. 4 pg/ml and 290. 2 ± 30. 5 pg/ml vs 250. 2 ± 20. 1 pg/ml, F = 16. 134, P <0. 001) , and the HFC group had a higher level than the LFC group (P < 0. 05) . The serum level of betatrophin was correlated with fat content and TC (r = 0. 301 and 0. 128, P = 0. 012 and 0. 027) . The multiple linear stepwise regression analysis showed that fat content was positively correlated with betatrophin (t = 3. 361, P = 0. 005) , TG (t = 2. 610, P = 0. 010) , and AST (t = 2. 015, P = 0. 012) and was negatively correlated with HDL-C (t =-1. 847, P = 0. 048) . Conclusion Liver fat content increases with the increase in the serum level of betatrophin. Serum betatrophin may be used as a predictive factor for NAFLD, which needs further research in the future.
- fatty liver /
- Betatrophin /
- correlation analysis

HTML全文

参考文献(21)

[1] LIU LL, REN Y, HE YH, et al. Research advances in chronic hepatitis B complicated by nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2017, 33 (3) :538-542. (in Chinese) 刘璐璐, 任艺, 何毅怀, 等.慢性乙型肝炎合并非酒精性脂肪性肝病的研究进展[J].临床肝胆病杂志, 2017, 33 (3) :538-542.

[2] ZHAO ZH, FAN JG. Nonalcoholic fatty liver diseases in AASLD 2016[J]. J Prac Hepatol, 2017, 20 (1) :21-24. (in Chinese) 赵泽华, 范建高. 2016年美国肝病年会非酒精性脂肪性肝病深度报道[J].实用肝脏病杂志, 2017, 20 (1) :21-24.

[3] LIU QS, DING B, DOU XB, et al. Activity of JNK pathway by cysteine contributes to the non-alcoholic steatohepatitis[J]. Chin J Clin Pharmacol Ther, 2016, 21 (4) :366-371. (in Chinese) 刘庆生, 丁滨, 窦晓兵, 等.基于JNK信号通路探究半胱氨酸在非酒精性脂肪性肝炎发病机制中的作用[J].中国临床药理学与治疗学, 2016, 21 (4) :366-371.

[4] ROTH CL, ELFERS C, LASS N, et al. Betatrophin:no relation to glucose metabolism or weight status in obese children before and after lifestyle intervention[J]. Pediatr Diabetes, 2017, 18 (6) :485-491.

[5] ESPES D, MARTINELL M, LILJEBACK H, et al. Betatrophin in diabetes mellitus:The epidemiological evidence in humans[J].Curr Diab Rep, 2015, 15 (12) :104-112.

[6] LEE YH, LEE SG, LEE CJ, et al. Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease:Animal and human studies[J]. Sci Rep, 2016, 6 (1) :24013.

[7] Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Guidelines for Management of non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124.

[8] HUANG GQ, ZONG Z, SUN Q, et al. Application of sound velocity tissue quantification in non-alcoholic fatty liver and cirrhosis diagnosis[J]. Chin J Nosocomiol, 2016, 26 (12) :2747-2749. (in Chinese) 黄国庆, 宗珍, 孙泉, 等.声速组织量化技术在非乙醇性脂肪肝及乙型肝炎肝硬化诊断中的应用研究[J].中华医院感染学杂志, 2016, 26 (12) :2747-2749.

[9] Expert Committee on the Diagnosis and Management of Fatty Liver Disease, Chinese Medical Association. Recommendation for the standardization of diagnosis and treatment of fatty liver disease[J]. J Clin Hepatol, 2013, 29 (9) :652-655. (in Chinese) 中国医师协会脂肪性肝病专家委员会.脂肪性肝病诊疗规范化的专家建议[J].临床肝胆病杂志, 2013, 29 (9) :652-655.

[10] CALAN M, YILMAZ O, KUME T, et al. Elevated circulating levels of betatrophin are associated with polycystic ovary syndrome[J].Endocrine, 2016, 53 (1) :271-279.

[11] JAMWAL R, DE LA MONTE SM, Ogasawara K, et al. Nonalcoholic fatty liver disease and diabetes is associated with decreased CYP3A4 protein expression and activity in human liver[J]. Mol Pharm, 2018, 34 (6) :1-11.

[12] KOPEC KL, BURNS D. Nonalcoholic fatty liver disease:A review of the spectrum of disease, diagnosis, and therapy[J]. Nutr Clin Pract, 2011, 26 (5) :565-576.

[13] DUMITRASCU DL, NEUMAN MG. Non-alcoholic fatty liver disease:An update on diagnosis[J]. Clujul Med, 2018, 91 (2) :147-150.

[14] VON LOEFFELHOLZ C, PFEIFFER AFH, LOCK JF, et al. ANGPTL8 (Betatrophin) is expressed in visceral adipose tissue and relates to human hepatic steatosis in two independent clinical collectives[J]. Horm Metab Res, 2017, 49 (5) :343-349.

[15] KONG FJ, MA LL, LI G, et al. Circulating betatrophin levels and gestational diabetes mellitus:A systematic review and meta-analysis[J]. PLo S One, 2017, 12 (1) :e0169941.

[16] FU Z, BERHANE F, FITE A, et al. Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity[J]. Sci Rep, 2014, 4 (1) :5013.

[17] CHALASANI N, WILSON L, KLEINER DE, et al. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2008, 48 (5) :829-834.

[18] CENGIZ M, OZENIRLER S, KOCABIYIK M. Serum beta-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis[J]. Eur J Gastroenterol Hepatol, 2016, 28 (1) :57-63.

[19] BATTAL F, TURKON H, AYLANC N, et al. Investigation of blood betatrophin levels in obese children with non-alcoholic fatty liver disease[J]. Pediatr Gastroenterol Hepatol Nutr, 2018, 21 (2) :111-117.

[20] HONG BS, LIU J, ZHENG J, et al. Angiopoietin-like protein 8/betatrophin correlates with hepatocellular lipid content independent of insulin resistance in non-alcoholic fatty liver disease patients[J]. J Diabetes Investing, 2017, 23 (1) :1-11.

[21] CAHOVA M, HABART D, OLEJAR T, et al. Lipasin/betatrophin is differentially expressed in liver and white adipose tissue without association with insulin resistance in Wistar and Goto-Kakizaki rats[J]. Physiol Res, 2017, 66 (2) :273-281.

施引文献

资源附件(0)

访问统计